Reboxetine

Reboxetine C화학적 특성, 용도, 생산

일반 설명

Most of the activity of reboxetine resides in the S,S-isomer(The marketed compound is RR and SS.) It is claimed to besuperior to fluoxetine in severe depression. It is marketed inEurope. At least three tricyclic compounds, desipramine,nortriptyline, and the technically tetracyclic maprotiline areSNERIs. They, of course, have typical characteristic TCAside effects but lower anticholinergic and H₁-antihistaminic(sedative) effects than dimethyl compounds. SNERIs areclinically effective antidepressants.
It would be expected that in the case of SNERIs,α2presynaptic receptors would be desensitized, after whichsustained NE transmission would be via one or more postsynapticreceptors; α1, β1, and β2 receptors are possibilities.

Clinical Use

Reboxetine is a nontricyclic SNRI in which the propylamine side chain of the TCAs is constrained into a morpholine ring. It is a potent and selective ligand for the NET, with a mechanism of action is similar to that of desipramine. Reboxetine is used for the treatment of major depressive disorders. It is a chiral compound that is marketed as a racemic mixture of R,R- and S,S-reboxetine. The antidepressant activity for reboxetine appears to reside with the S,S-(+)-enantiomer, which has approximately twofold the inhibition potency of the R,R-enantiomer. It is well tolerated, with different adverse-event profiles, and it appears to be at least as effective as the SSRIs in the treatment of depressive illness. Currently, it is available only in Europe and is under U.S. FDA review. It preferentially inhibits the reuptake of NE (5-HT :NE ratio, 8). Reboxetine is not metabolized by the polymorphic isoforms, CYP2D6 or CYP2C19, and may offer a valuable alternative to the secondary amine TCAs in the treatment of major depression. Reboxetine is likely to become a promising alternative for patients who have failed treatment with or do not tolerate serotonergic antidepressants.

부작용

Reboxetine is relatively well tolerated, with insomnia, sweating, constipation, and dry mouth being commonly reported adverse events. Hypotension and urinary hesitancy occur at lower rates than with the TCAs. When compared with the SSRIs, reboxetine is associated with lower rates of nausea, somnolence, and diarrhea.

Drug interactions

Reboxetine seems to be an antidepressant that has negligible interference with the pharmacokinetics of other drugs; thus, fewer drug–drug interactions are expected. It also may be possible to use reboxetine in combination with MAOIs, because it has no inhibitory effect on this enzyme, which would avoid tyramineinduced hypertensive reactions.

Reboxetine 준비 용품 및 원자재

원자재

준비 용품

Reboxetine 공급 업체

공급자	전화	이메일	국가	제품 수	이점
CONIER CHEM AND PHARMA LIMITED	+8618523575427	sales@conier.com	China	47465	58
Career Henan Chemica Co	+86-0371-86658258 15093356674;	laboratory@coreychem.com	China	30255	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	29474	58
Dayang Chem (Hangzhou) Co.,Ltd.	571-88938639 +8617705817739	info@dycnchem.com	CHINA	52867	58
Hebei Duling International Trade Co. LTD	+8618032673083	sales05@hbduling.cn	China	15747	58
LEAPCHEM CO., LTD.	+86-852-30606658	market18@leapchem.com	China	43348	58
Amadis Chemical Company Limited	571-89925085	sales@amadischem.com	China	131981	58
LGM Pharma	1-(800)-881-8210	inquiries@lgmpharma.com	United States	2127	70
Beijing HuaMeiHuLiBiological Chemical	010-56205725	waley188@sohu.com	China	12338	58
Nanjing Sunlida Biological Technology Co., Ltd.	025-57798810	sales@sunlidabio.com	China	3750	55

Reboxetine 관련 검색: